Supernus to Present at the Cowen 43rd Annual Health Care Conference
March 01, 2023 16:55 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., March 01, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Fourth Quarter and Full Year 2022 Financial Results
February 28, 2023 16:05 ET
|
Supernus Pharmaceuticals, Inc.
Full Year 2022 total revenues of $667.2 million, a 15% increase compared to full year 2021Fourth quarter 2022 Qelbree® net product sales of $23.6 million increased 29% compared to third quarter of...
Supernus Enters Into $150 Million Credit Facility
February 14, 2023 16:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023
February 09, 2023 18:15 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference
November 22, 2022 17:00 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Present at Two November Healthcare Conferences
November 08, 2022 17:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Third Quarter 2022 Financial Results
November 08, 2022 16:05 ET
|
Supernus Pharmaceuticals, Inc.
Third quarter 2022 total revenues of $177.4 million, a 19% increase compared to third quarter 2021Increasing full year 2022 operating earnings guidance to $35 million to $45 million, from $20 million...
Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022
October 25, 2022 16:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Provides Regulatory Update on SPN-830
October 10, 2022 08:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Present at the 2022 Wells Fargo Healthcare Conference
August 31, 2022 16:00 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...